Jessica Shore

Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa‐2a in HIV‐1–Monoinfected Participants: A Phase II Clinical Trial

David M. Asmuth, Robert L. Murphy, Susan L. Rosenkranz et al. · The Journal of Infectious Diseases · 2010 · 118 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen

Mariana Gerschenson, Courtney Kim, Baiba Berzins et al. · Journal of Antimicrobial Chemotherapy · 2009 · 44 citations · Full text

Life Sciences, Biochemistry, Pharmacotherapy +16

Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine

Kimberly Y. Smith, C. Tierney, Katie R. Mollan et al. · Clinical Infectious Diseases · 2013 · 33 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202

Charles S. Venuto, Katie R. Mollan, Qing Ma et al. · Journal of Antimicrobial Chemotherapy · 2014 · 19 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202

Cindy J. Bednasz, Charles S. Venuto, Qing Ma et al. · Antimicrobial Agents and Chemotherapy · 2019 · 16 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16